Get the scoop on pre-market movers and shakers in the US stock market.

Artelo Biosciences Soars 12.26% on Positive Drug Data

Ainvest Pre-Market RadarWednesday, Jul 9, 2025 6:02 am ET

1min read

Artelo Biosciences' stock surged 12.26% in pre-market trading on July 9, 2025, driven by positive preclinical data for its drug candidate ART12.11.

Artelo Biosciences reported that ART12.11 demonstrated significant antidepressant-like effects and cognitive benefits in animal studies. The 28-day treatment regimen with ART12.11 reversed behavioral impairments in male rats exposed to chronic stress, showing efficacy comparable to sertraline, a commonly prescribed antidepressant.

The company's CEO, Gregory D. Gorgas, expressed particular encouragement over the strong antidepressant effects observed in the preclinical data. This positive data has sparked investor interest, leading to a notable increase in the stock price.

Artelo Biosciences also announced positive Phase 1 data for its non-opioid analgesic candidate, further bolstering investor confidence in the company's pipeline. The preclinical data for ART12.11 suggests its potential to treat depression and cognitive deficits associated with chronic stress, aligning with the company's goal of developing innovative therapies for mental health conditions.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.